Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands

J. G. Kuiper, R. J. Sanchez, E. Houben, E. M. Heintjes, F. J. A. Penning-van Beest, I. Khan, M. van Riemsdijk, R. M. C. Herings

Research output: Contribution to journalArticleAcademicpeer-review


PURPOSE: This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands. METHODS: From the PHARMO Database Network, patients aged >/=18 years with an LDL-C measurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemic stroke, peripheral arterial disease, and diabetes mellitus. LMT use and LDL-C goal attainment at the index date was assessed. FINDINGS: Of 61 839 patients who met the inclusion criteria, 1132 (2%) had FH, 2431 (4%) had recent ACS, 6292 (10%) had coronary heart disease, 2868 (5%) had ischemic stroke, 3017 (5%) had peripheral arterial disease, and 46 099 (75%) had diabetes mellitus. Overall, 67% of patients were receiving LMT. Use of LMT ranged from 77% for recent ACS to 53% for FH, and standard-potency statins were the most prescribed. The percentage attaining an LDL-C goal of
Original languageEnglish
Pages (from-to)819-827 e1
JournalClin Ther
Issue number4
Publication statusPublished - 2017


  • Adult Aged Aged, 80 and over Cholesterol, LDL/*blood Coronary Disease/blood/*drug therapy Diabetes Mellitus/blood/*drug therapy Female Goals Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use Hyperlipoproteinemia Type II/blood/*drug therapy Male Middle Aged Myocardial Ischemia/blood/*drug therapy Netherlands Peripheral Arterial Disease/blood/*drug therapy Risk Ldl-c cardiovascular disease prevention statin

Cite this